Skip to main content

Table 4 Mazzotti reactions after OCP-patch and LTS-2 patch application

From: Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch

Mazzotti reactions

After OCP-patch

After LTS-2 patch

Itching at patch application site: n (%)*

19 (63.3 %) at OCP-patch site

6 (20.0 %) at LTS-2 patch site

  

3 (10.0 %) at OCP-patch siteb

 Start (hrs after patch application)a Mean ± SD

12.6 ± 13.4

6.9 ± 6.9 at LTS-2 patch site

 Start (hrs after patch application)a Range (Median)

0.8–52.0 (8.2)

1.5–19.4 (4.1) at LTS-2 patch site

  

0.1, 0.5, 4.1 + 36.1 – at OCP-patch

 Duration (hrs): Mean ± SDa, **

8.9 ± 11.8

1.0 ± 2.5 at LTS2 patch

 Duration (hrs): Range (Median)

0–56 (7.63)

0–8.9 (0) – at LTS–2 patch

 Duration (hrs)

 

1.1, 4, 6 + 12 – at OCP-patch

Itching involving the whole body: n (%)

5 (16.7)

2 (6.7 %)

 Start (hrs after patch application)

4.1, 28.1, 51.9, 36.4, 4.3

5.7, 13.2

 Duration (hrs)

7.9, 8.0, 8.2, 23.8, 55.9

6.3, 15.0

Itching at back

1 (3.3 %)

0

Other clinical Mazzotti reactions

  

 Burning sensation at patch sitec

2 (6.7 %)

0

 Pain at patch site

1 (3.3 %)

0

Haematological/biochemical reactions

  

 Leucocytosis with increase in peripheral granulocytes

4 (13.3)

6 (20.0 %)

 Increase in AST

3 (10 %)d

0

 Increase in ALT

3 (10 %)d

4 (13.3 %) + 2 (6.7 %d)

 Increase in ALP

0

2 (6.7 %)

  1. * p = 0.0015, ** p = 0.0014, adescriptive statistics calculated across subjects with itching, bincludes 1 subject who had no itching at the OCP-patch site after the OCP-patch application, cdescribed by the participants as ‘pepper on the skin’, duration 3.3 and 6.4 h, resp. dElevations persisted into period after LTS-2 application and in 2 participants ALT elevation increased from grade 1 after OCP-patch application to grade 2 after LTS-2 patch application